<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319082</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-KXL-401</org_study_id>
    <nct_id>NCT03319082</nct_id>
  </id_info>
  <brief_title>Observational Registry to Assess Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery</brief_title>
  <acronym>CXL</acronym>
  <official_title>A Phase IV Observational Registry to Assess the Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avedro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avedro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this post market registry are to evaluate the safety and durability of
      treatment effect up to 3 years following cross-linking performed with Photrexa Viscous
      (riboflavin 5'- phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-
      phosphate ophthalmic solution), and the KXL System in patients with corneal ectasia following
      refractive surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 200 patients who are planning to undergo or have undergone CXL for the
      treatment of corneal ectasia following refractive surgery in one or both eyes according to
      the prescribing information in the Photrexa Viscous and Photrexa Package Insert could be
      enrolled. Patients will be followed for safety and effectiveness at Months 3, 6, 12, 24 and
      36 following cross-linking treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Kmax</measure>
    <time_frame>36 months</time_frame>
    <description>Change from pretreatment baseline in maximum corneal curvature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>36 month</time_frame>
    <description>Change from pretreatment baseline in BCVA</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>CXL Group</arm_group_label>
    <description>Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Corneal Collagen Cross-linking</intervention_name>
    <description>Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).</description>
    <arm_group_label>CXL Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with corneal ectasia following refractive surgery who are planning to undergo or
        have undergone corneal collagen cross-linking in one or both eyes according to the Photrexa
        Viscous and Photrexa prescribing information.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be at least 18 years of age, male or female, of any race;

          2. Provide written informed consent and sign a HIPAA form;

          3. Willingness and ability to follow all instructions and comply with schedule for study
             visits;

          4. Have a diagnosis of corneal ectasia post-refractive surgery (such as LASIK, PRK);

          5. Planning to undergo (or have undergone within the past 90 days) corneal collagen
             cross-linking with PHOTREXA VISCOUS/ PHOTREXA and the KXL System, per the prescribing
             information (NOTE: Complete treatment and follow-up data, including any
             product-related events at time of procedure through the time of enrollment must be
             available);

          6. For females capable of becoming pregnant, agree to have urine pregnancy testing
             performed prior to enrolling in the registry; must not be pregnant or lactating.

        Exclusion Criteria:

          1. If female, be pregnant, nursing, or have a positive urine pregnancy test prior to
             enrollment in the registry;

          2. The Investigator may exclude or discontinue any patient for any sound medical reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vineeta Belanger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Avedro, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Schumacher</last_name>
    <phone>7818957823</phone>
    <email>sSchumacher@avedro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanfrod University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Enriquez, COT</last_name>
      <phone>650-498-4573</phone>
      <email>Tenriquez@sanfordhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Edward Manche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Vision Center</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nic Jacobs</last_name>
      <phone>952-835-1235</phone>
      <phone_ext>205</phone_ext>
      <email>nic.jacobs@chuvision.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive EyeCare of Central Ohio</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Coury</last_name>
      <phone>614-890-5692</phone>
      <email>dcoury@compeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Beckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Partners of PA, P.C.</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Petrocella, COT</last_name>
      <phone>484-434-2606</phone>
      <email>CPetrocella@oppdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Brandon Ayres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slade &amp; Baker Vision</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chadisty Pauly</last_name>
      <phone>713-626-5544</phone>
      <email>chad@visiontexas.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Slade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Avila, OD</last_name>
      <phone>801-568-0200</phone>
      <email>mavila@hoopesvision.com</email>
    </contact>
    <investigator>
      <last_name>Majid Moshirfar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>See Clearly Vision Group</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Suy</last_name>
      <phone>703-827-4125</phone>
      <email>jsuy@seeclearly.com</email>
    </contact>
    <investigator>
      <last_name>Khoa D Hoang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=peter+hersh</url>
    <description>U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery</description>
  </link>
  <reference>
    <citation>Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK; U.S. Crosslinking Study Group. U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery. Ophthalmology. 2017 Oct;124(10):1475-1484. doi: 10.1016/j.ophtha.2017.05.036. Epub 2017 Jun 24.</citation>
    <PMID>28655538</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

